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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Some commonly prescribed medications
can be a hazardous to traffic safety.
• Fifteen categorization systems are currently
available in Europe. However, none of these
systems clearly reports the methodology
that was followed in order to categorize
medications that impair driving.
• None of the existing categorization systems
are currently implemented at European
level.
WHAT THIS STUDY ADDS
• This study describes standardized and
harmonized criteria to categorize
medications according to their potential to
impair fitness to drive.
• This study proposes a European
categorization system of medications that
impair driving that covers all the most
frequently prescribed medications.
• The proposed categorization system can be
seen as a tool to improve prescribing and
dispensing procedures of medications that
impair driving as well as an instrument to
make patients aware of the role medications
play in traffic safety.
AIMS
To illustrate (i) the criteria and the development of the DRUID
categorization system, (ii) the number of medicines that have currently
been categorized, (iii) the added value of the DRUID categorization
system and (iv) the next steps in the implementation of the DRUID
system.
METHODS
The development of the DRUID categorization system was based on
several criteria. The following steps were considered: (i) conditions of
use of the medicine, (ii) pharmacodynamic and pharmacokinetic data,
(iii) pharmacovigilance data, including prevalence of undesirable
effects, (iv) experimental and epidemiological data, (v) additional data
derived from the patient information leaflet, existing categorization
systems and (vi) final categorization. DRUID proposed four tiered
categories for medicines and driving.
RESULTS
In total, 3054 medicines were reviewed and over 1541 medicines were
categorized (the rest were no longer on the EU market). Nearly half of
the 1541 medicines were categorized 0 (no or negligible influence on
fitness to drive), about 26% were placed in category I (minor influence
on fitness to drive) and 17% were categorized as II or III (moderate or
severe influence on fitness to drive).
CONCLUSIONS
The current DRUID categorization system established and defined
standardized and harmonized criteria to categorize commonly used
medications, based on their influence on fitness to drive. Further efforts
are needed to implement the DRUID categorization system at a
European level and further activities should be undertaken in order to
reinforce the awareness of health care professionals and patients on
the effects of medicines on fitness to drive.
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Introduction
Driving a motor vehicle is a multifaceted task and it
requires appropriate cognitive and psychomotor skills (e.g.
alertness, concentration, reaction time, visual acuity) [1–3].
Medication can adversely affect these driving-related skills,
and, consequently, be a hazard to traffic safety [4, 5].
The European Council Directive 83/570/EEC of October
1983 established that the summary of product character-
istics (SmPC) has to contain information on medicines’
‘effects on the ability to drive and to use machines’ [6]. In
October 1991 the European Committee for Medicinal
Products for Human Use (CHMP) provided a Note for Guid-
ance for the SmPC in which it was stated that section 4.7
of medications registered from 1 January 1992 had to
indicate, on the basis of the pharmacodynamic profile,
reported adverse drug reactions (ADRs) and/or impair-
ment of driving performance or performance related to
driving based on three different levels of impairment with
respect to the ability to drive and/or operate machines [7,
8]. However, this rule has never been implemented [9].
In September 2009, a new SmPC guideline was issued,
which established that ‘on the basis of the pharmacody-
namic and pharmacokinetic profile, reported adverse reac-
tions and/or specific studies in a relevant target population
addressing the performance related to driving and road
safety or using machines, specify whether the medicinal
product has: (i) no or negligible influence, (ii) minor influ-
ence, (iii) moderate influence or (iv) major influence on
these abilities’ [10]. These new guidelines were partly
based on the proposal sent to the European Medicines
Agency (EMA) by DRUID Work Package (WP) 4 partners
during the consultation phase for the revision of the SmPC
guidelines, in March 2008.
Despite the above-mentioned regulations, at this
moment, a European categorization system has not yet
been established, and warning systems for medications
that potentially impair driving have mainly been devel-
oped and/or implemented at national levels [8, 11].
Existing categorization systems on medicines
and driving
A review of the existing classification/categorization and
labelling systems for medicines and driving was per-
formed in 2008 and 15 different approaches were identi-
fied [12]. The categorization/labelling systems differed
significantly and were not standardized, making them dif-
ficult to understand. In most cases [13–17], the categoriza-
tion systems were developed by different and unrelated
bodies, societies or researchers and were, in general, aimed
at improving the prescription and dispensing of medicines
to the patients and drivers. The identified categorization
systems often included a limited number of medicines
belonging to a few different therapeutic groups (e.g.
antihistamines, anxiolytics, etc) and were not legally
binding. However, the review also identified a couple
categorization/labelling systems that were developed by
regulatory bodies, included the use of pictograms and
were legally binding [18, 19].
In 1973, the Netherlands became the first country to
introduce a list of medications that can impair driving abili-
ties. Besides the list, the use of a yellow warning sticker on
medication boxes was established and implemented [20].
In 1981, Denmark, Finland, Iceland, Norway and Sweden
adopted a warning label. The label consisted of a red tri-
angle printed on packages of ‘especially dangerous’ medi-
cations, and it is currently still in use in Denmark, Finland,
and Norway. Most recently, France [18] and Spain [19]
developed a categorization/labelling of all available medi-
cines using technical interdisciplinary groups formed from
their respective national medicines regulatory agency [21,
22] The introduction of pictograms (three-tier labelling
system in France and two-tier in Spain) to be added on the
packages of certain medicines became legally binding in
both countries.
It is important to point out that although different cat-
egorization systems are currently available across Europe,
the criteria for the establishment of a categorization
system for potentially impairing medications has neither
been clearly described nor published nor been officially
adopted at European level [12].
The DRUID project and its categorization
system on medicines and driving
The Driving under the Influence of Drugs, Alcohol and
Medicines (DRUID) project is an integrated project funded
by the European Commission.The main aim of DRUID is to
give scientific support to European Union (EU) transport
policy by establishing guidelines and measures that
combat impaired driving [23].
The DRUID WP4 aims to provide the basis and
the methodology for the development of a European
classification/labelling system for medications with
respect to their impact on fitness to drive. Furthermore, it
also focuses on the development of a classification of rel-
evant therapeutic groups that are currently on the market
in Europe as well as new medications approved by the
European Medicines Agency (EMA) in the years 2007–2009
[23].
Aims of the study
This paper illustrates: (i) the criteria and the development
of the DRUID categorization system, (ii) the number of
medicines that have currently been categorized and the
distribution of the DRUID categories across the Anatomical
Therapeutic Chemical (ATC) index, (iii) the importance of
this system, its implications for health care professionals
(HCPs) and patients, and its strengths and limitations and
(iv) the next steps in the implementation of the DRUID
system and some general recommendations.
Medicines and fitness to drive
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Methods
The development of the DRUID categorization system was
based on the criteria that were established by a group of
experts in the field of medicines and driving, involved in
the DRUID WP4, and based on their consensus [24].
The four DRUID categories on medicines and
driving
In 2006, the DRUID group established and agreed that,
according to its influence on fitness to drive, a medicine
could be categorized as follows (Figure 1):
• category 0 (no or negligible influence on fitness to drive),
• category I (minor influence on fitness to drive),
• category II (moderate influence on fitness to drive),
• category III (severe influence on fitness to drive).
The proposed categorization is in line with the recently
approved SmPC guidelines, which were adopted in Sep-
tember 2009 by the EMA [10].
Furthermore, the DRUID experts decided to develop,
for each category, practical information to be used by HCPs
for patient counselling purposes as well as simple warning
labels that could be easily understood by patients (label-
ling) (Figure 1).
The DRUID categorization of medicines and
driving
The ATC classification list [25] was used as a starting point
for the selection of the relevant groups of medicines to be
categorized. The aim was to categorize all available medi-
cines on the European Union market for each selected ATC
group.
Figure 2 shows the process that was followed in order
to identify all those medications that are currently avail-
able on the EU market. In general, a medicine was consid-
ered available on the EU market if it was commercialized in
at least two of the following European countries: Belgium,
France, Germany, Greece, the Netherlands, Spain, United
Kingdom and Ireland. If the above-mentioned criterion
was not fulfilled, the medication was not included in the
categorization process.
After a meeting with the French Health Products Safety
Agency (AFSSAPS) experts in categorizing medications
affecting driving performance, the DRUID WP4 group
Presumed to be safe or unlikely to
produce an effect on fitness to drive.
- Confirm that the medicine will be
  safe for driving, provided that
  combinations with alcohol and other
  psychotropic medicines are excluded. 
- Inform the patient that impairing 
  side effects may occur especially 
  during the first days and that they
  have a negative influence on his/her
  driving ability.
- Give the patient the advice not to 
  drive if these side effects occur.
[no warning needed]
Category 0
Likely to produce minor adverse
effects on fitness to drive.
Category 1
- Inform the patient about the possible
  impairing side effects and the
  negative influence on his/her driving
  ability.
- Advise the patient not to drive
  during the first few days of the
  treatment.
- If possible prescribe a safer medicing,
  if effective and acceptable to the
  patient.
Likely to produce moderate adverse
effects on fitness to drive.
Category 2
Do not drive without having read the
relevant section on driving
impairment in the package insert. 
Warning level 1






























































Read the patient information leaflet
before driving
Be very careful!
Don’t drive without the advice
of your GP or pharmacist
Attention: danger!
Do not drive. Seek medical advice
before driving again
0 1 2 3 0 1 2 3 0 1 2 3
Effects on ability to drive
Pictograms
Effects on ability to drive
Do not drive without advice of a health
care professional. Read the relevant
sections on driving impairment in the
package insert before consulting the
physican or pharmacist
Warning level 1
- Inform the patient about the possible
  impairing side effects and the
  negative influence on his/her driving
  ability.
- Urgently advise the patient not to 
  drive.
- Consider prescribing a safer
  medicine, if acceptable to the
  patient.
Likely to produce severe effects
on fitness to drive or presumed to
be potentially dangerous.
Category 3
Do not drive. Seek medical advice
after a period of treatment about the
conditions to restart driving again.
Warning level 3
Figure 1
DRUID categorization system for medicines and driving
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decided to adopt a procedure similar to the one used in
France and more specifically to evaluate the following
information and data:
1 Conditions of use of the medicine in the EU market
2 Pharmacodynamic and pharmacokinetic data
3 Pharmacovigilance data (including prevalence of unde-
sirable effects reported in the SmPC)
4 Experimental and epidemiological data
5 Additional data derived from the patient information
leaflet (PIL) and existing categorization systems and
information from other sources
6 Synthesis and final categorization.
Figures 3 and 4 summarize the methodology that was fol-
lowed in order to assign a category to a selected medicine.
The conditions of use of the medicine, pharmacody-
namic, pharmacokinetic and pharmacovigilance data
(including prevalence of undesirable effects) were derived
from the SmPC [10], whereas point 4 (experimental and
epidemiological data) was based on a scientific literature
search.
The SmPC and PIL of the selected medications were
found online, in one of the following websites: Medicines
and Healthcare products Regulatory Agency (MHRA) [26],
Electronic Medicines Compendium (eMC) [27], or Irish
Medicines Board (IMB) [28], or retrieved from national
medicines regulatory agencies as needed. In case of
recently approved active substances, the SmPC was found
on the EMA website [29]. The selection of the above men-
tioned medicines regulatory affairs agencies was simply
based on the fact that the required information had to be
ATC list
http://www.whocc.no/atc_ddd_index/
Check with the European Medicines Agency
Yes
Centrally granted by European
Medicines Agency
http://www.ema.europa.eu/









Not available at EU
Market because not
granted or withdrawn
form the EU Member
States Market




Check the availability in Belgium, France,
Germany, Greece, the Nederlands, Spain,
United Kingdom, Ireland.
Consults at respective National Medicines
Agencies
Is the medicine available at European
Union Market?
Process of the categorization and labelling of medicines and




Identification process of medicines available on the EU market
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available either in English or in a language that could be
fully understood by DRUID WP4 partners.
Specific sections of the SmPC and PIL were used to
retrieve details on the active substance presentations and
strength, indications, posology, route of administration
(step 1), pharmacodynamic and pharmacokinetic profile
(step 2), effects on the ability to drive and use machines
(step 5) and undesirable effects related to driving and
operating machines (step 3).
With respect to the undesirable effects, their occur-
rence was considered as a key point, especially if experi-
mental and epidemiological data were lacking or limited.
This type of information was found in section 4.8 of the
SmPC and, when not available, was retrieved from the
available literature.
Generally speaking, only those adverse reactions that
could affect the ability to drive and that were reported as
common (>1/100,<1/10) or very common (>1/10) were con-
sidered to be relevant, as in accordance with the most recent
EMA categorization on frequency of undesirable effects, side
effects or adverse reactions. In cases of rare or very rare unde-
sirable effects,or if certain severely impairing effects occur,for
example sudden sleep attacks, the DRUID partners recom-
mended that this should be mentioned in the PIL.
Table 1 reports the criteria used for assigning a medi-
cine to a specific category whenever experimental or epi-
demiological data were lacking or limited.
Table 2 lists the undesirable effects that could impair
the ability to drive, and, therefore, were taken into account
in the categorization process.
Data sources for the scientific literature evaluation
included the electronic databases Medline, Science Direct
and PsycINFO. The search was performed by using these
combinations of keywords: ‘active substance name and
psychomotor performance’, ‘active substance name and
automobile driving’ and ‘active substance name and traffic
accidents’. The final data selection was limited to full text
articles published in English and other languages that
included references to side effects, experimental and phar-
macoepidemiological studies and case reports on each
active substance to be categorized and its possible driving
impairment. No restrictions concerning the publication
year were applied.
Additional steps consisted of reviewing section 4.7 of
the SmPC ‘Effects on ability to drive and use machines’ and
the PIL section on ‘Driving and using machines’ as well as
reviewing the previous categorization (if available) of the
medicine in Belgium, France, the Netherlands, Spain and
the International Council on Alcohol, Drugs and Traffic
Safety (ICADTS) list.
In the cases of severely impairing medicines, recently
approved medications, or medicines belonging to the ATC
groups N and R06, all the collected data were compiled in
fact sheets with a standardized lay-out, which were used
Methodology for the DRUID categorization and labelling system for medicines and driving
a) No or negligible
     influence








































No demonstration of CNS side
effects or other unwanted effects
on driving
No influence expected
No demonstration of impairment
No influence expected
Some demonstration of CNS side
effects or unwanted effects that
impair driving





Demonstration of CNS side effects
(not severe) or unwanted effects
that impair driving
Impairment of driving performance
is seen in various experimental
studies. In epidemiological studies
a significant increased risk is
demonstrated
Severe influence expected
Demonstration of CNS side effects
(severe) or unwanted effects that
impair driving
Gross impairment of driving
performance or performance
related to driving is repeatedly
seen. In epidemiological studies a
significant and meaningful
increased risk is demonstrated
No further data on impairment Some data on possible impairment Various data on impairment (not
severe)
Data on severe impairment
No or negligible influence Minor influence Moderate influence Major influence
Figure 3
Methodology for the DRUID categorization system for medicines and driving
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Medication approved by
the European Medicines Agency
Information to be found at:
http://www.ema.europa.eu
Medication approved by EU Member States
Information to be found at: MHRA, eMC, IMB
Step 1
Conditions of use of the medication
SmPC sections
2. Qualitative and quantitative composition
3. Pharmaceutical form
4. Clinical particulars
    4.1 Therapeutic indications
    4.2 Posology and method of administration
SmPC sections
5. Pharmacological properties
      5.1 Pharmacodynamic properties
      5.2 Pharmacokinetic properties
SmPC sections
4.8 Undesirable effects
Literature search in MEDLINE, ScienceDirect,
PsycINFO
(Use of specific keywords related to driving fitness
and traffic accident risks)
SmPC and PIL sections
- SmPC: 4.7 Effects on ability to drive and use
  machines
- PIL: driving and using machines
- Existing categorization systems (Belgium, France,
ICADTS, Spain, The Netherlands)
Categorization proposal
Discussion with WP4 partners.
ØØ
Agreement and approval of the proposed
categorization
Place and date of agreement
If new evidence merges, it will be possible to review
the assigned category by following the steps reported
above
Step 2










Modification of the assigned category, in
case new evidence will emerge
Figure 4
Flowchart representing the methodology that was followed during the DRUID categorization process. Legend: SmPC, Summary of Product Characteristics;
PIL, Patient Information Leaflet; EMA, European Medicines Agency; MHRA, Medicines and Healthcare products Regulatory Agency; eMC, Electronic Medicines
Compendium; IMB, Irish Medicines Board
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during the active substance evaluation procedure and the
approval of its final category.
After evaluating all the available data, a provisional cat-
egory was assigned to each active substance. The provi-
sional category was proposed and discussed during WP4
meetings, where a final and definitive category was
assigned and approved by all WP4 partners.
It is important to note that the DRUID methodology on
the categorization of medicines affecting driving fitness
allows not only to categorize an active substance but also
to revise a previously assigned category, in cases where
new evidence emerges, by following the same 5 step
approach (Figure 4).
Medicines to be categorized
The following ATC groups were considered in the catego-
rization process:
A – Alimentary tract and metabolism
B – Blood and blood forming organs
C – Cardiovascular system
D – Dermatologicals
M – Musculoskeletal system
N – Nervous system
R – Respiratory system
S – Sensory organs
Results
Three thousand fifty-four medicines were considered for
inclusion into the categorization process. Of these 3054
medicines, 1513 were not categorized because they were
not available on the EU market.
The distribution of the 1541 categorized medicines
(see supplementary data) was as follows (Figure 5): Cat-
egory 0 50.3%, Category I 26.0%, Category II 11.2%, Cat-
egory III 5.8%, Multiple categories 4.4% and Depending on
the medicine in combination 2.3%. This figure shows that
the majority of medications belong to either category 0 or
category I (Figure 5).
It is important to note that the term ‘multiple catego-
ries’ refers to the fact that a certain medication could be
included in more than one category.There could be several
reasons for this, such as different routes of administration
of the same active substances (e.g. topical, oral, parenteral,
etc), different pharmaceutical formulations (e.g. aqueous
vehicle, cream, drops or ointment, etc.), different dosages
administered, etc.
With respect to the terminology ‘depending on medi-
cines in combination’, it is relevant to observe that this
approach was used when the categorization depended on
the combination of the medication under evaluation with
another active substance. In these cases, since the ATC clas-
sification [18] often did not report the medicine used in
combination, it was decided not to use a final category but
to follow the above-mentioned approach.
Table 3 gives an overview of the distribution of the
medicines in each category, stratified by ATC group. It is
apparent from this table that the N group contains the
highest number of category III medications. A detailed
description of the category distribution within the N group
is depicted in Table 4. The N05 sub-group shows the
highest number of category III medicines, followed by the
Table 1
Relationship of the undesirable effects category in the SmPC to the
DRUID categorization system
Declaration of undesirable
effects that can potentially
impair the fitness to drive
safely DRUID category
Very common (>1/10) Category II or III
Common (>1/100, <1/10) Category I
Rare (>1/10 000, <1/1000) Category 0
or very rare (<1/10 000)
Table 2
List of undesirable effects that can impair driving ability that were con-




Selection of side effects that can impair the
ability to drive safely
Nervous system
disorders
• Somnolence, dizziness, drowsiness
• Confusion – cognitive disorder- disorientation
• Involuntary movement disorders: ataxia, tremor,
parkinsonism, acute dystonic (dyskinesia) and
dyskinetic reactions (dystonia)
• Convulsions – seizures
Psychiatric
disorders
• Perception disturbances (hallucination, visual
hallucination, auditory hallucination, illusion)
• Psychotic reactions and psychotic disorder (including
paranoia psychosis)
• [Other: emotional lability, mood swings, aggression,
nervousness, irritability, personality disorders, thinking
abnormal, abnormal behaviour, euphoric mood,
restlessness (emotional state of excitement),
depersonalization]
Eye disorders • Diplopia or double vision,
• Blurred vision
• Accommodation disorders
• Visual acuity reduced
• Photophobia
• [Other: visual field defect, peripheral vision loss,









Vascular disorders • Hypotension
S. Ravera et al.
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N01 sub-group. The N05 sub-group also contains the
highest number of medications assigned to more than one
category.
Discussion
The current DRUID categorization system establishes and
defines standardized and harmonized criteria to catego-
rize commonly prescribed medicines based on their influ-
ence on fitness to drive. To date, this system nearly
embraces the full ATC index and it intends to provide a
complete coverage of the most commonly prescribed
medications in Europe. This categorization procedure is
developed by a European group of experts and is meant to
go beyond the national context to address a broader Euro-
pean scenario and involve different facets of health care
practice.
The categorization system could be seen as a tool to
improve prescribing and dispensing procedures both at a
national and European level and, therefore, as an instru-
ment to inform and involve HCPs better [11, 30]. In this
respect, it is important that HCPs know the fundamentals
of the categorization system and use it properly in order to
inform fully their patients about the risks of driving under
the influence of impairing medicines. Furthermore, HCPs
should be able to distinguish between the four levels of
impairment and, if possible, choose the least impairing
medication within the same therapeutic group. Moreover,
this system should encourage HCPs to update their knowl-


















Distribution of the 1541 categorized medicines within the different DRUID categories
Table 3












A – alimentary tract and metabolism 243 234 69 8 1 4 4 563
B – blood and blood forming organs 86 135 1 1 2 225
C – cardiovascular system 246 90 200 11 1 548
D – dermatologicals 156 192 1 4 353
M – musculo-skeletal system 88 22 44 28 15 197
N – nervous system 346 9 30 86 53 36 560
R – respiratory system 195 62 24 32 10 5 14 342
S – sensory organs 153 31 31 6 11 18 16 266
Total 1513 775 400 172 90 68 36 3054
Medicines and fitness to drive
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edge on medicines and driving in order to be prepared
to answer questions that patients might have on this topic
[8, 11].
The DRUID categorization system should also be used
as a tool to motivate HCPs to provide patients with clear
information, communicate to patients the risk associated
with driving under the influence of medicines and catalyze
health care professional-patient discussions, leading to
both safer prescriptions and patients who are more con-
scientious about their decision on whether or not to drive
[8, 11, 30].
This classification could be a useful tool in helping
patients be more involved in the decision-making process,
understand the hazards of some medications to traffic
safety and remind them to use caution while driving until
their individual responses to their therapy have been well
established.
To our knowledge, this is the first time that the Euro-
pean Commission assigned an expert group in the field of
medicines and driving the task of establishing the criteria
for a European classification system and developing a cat-
egorization system for relevant therapeutic groups of
medications with respect to their impact on driving skills.
The categorization efforts were carried out by an interna-
tional group of DRUID partners, coming from six different
institutions in Europe, and gathered all their scientific com-
petence, knowledge, expertise, and experience in the field
of road safety research and practice. All the available data
from multiple sources were collected according to a stan-
dardized step-by-step procedure, which allows for the
future maintenance and/or revision of the current DRUID
categorization system as new evidence emerges in the
future, and it also allows for the constitution of a consistent
evidence-based classification methodology to categorize
new medications prior to their market authorization. Last
but not least, as reported above, the DRUID categorization
system encompasses the entire ATC list. Therefore, it is the
first categorization system to provide a nearly complete
overview of the influence of frequently prescribed medi-
cations on the ability to drive. Additionally, in the cases of
severely impairing medications (e.g. medicines from the N
group), the system is integrated with fact sheets which
concisely emphasize the key points of the categorization
and can be easily used as a support mechanism in HCPs’
daily practice [24].
Lastly, some limitations of the DRUID categorization
system should be considered. In particular, special atten-
tion should be paid to the fact that a category is attributed
Table 4
Number of medicines from the ATC group, N-NERVOUS SYSTEM MEDICINES, categorized in each DRUID category











N01 ANAESTHETICS 31 3 3 1 12 10 60
N01A Anaesthetics, general 20 11 1 32
N01B Anaesthetics, local 11 3 3 1 1 9 28
N02 ANALGESICS 93 2 7 10 3 7 122
N02A Opioids 31 2 7 40
N02B Other analgesics and antipyretics 52 2 6 1 1 62
N02C Antimigraine preparations 10 1 9 20
N03 ANTIEPILEPTICS 23 14 4 2 43
N03A Antiepileptics 23 14 4 2 43
N04 ANTIPARKINSON 16 3 16 1 36
N04A Anticholinergic agents 10 4 1 15
N04B Dopaminergic agents 6 3 12 21
N05 PSYCHOLEPTICS 107 4 16 26 12 165
N05A Antipsychotics 31 13 8 9 65
N05B Anxiolytics 23 1 3 7 1 35
N05C Hypnotics and sedatives 53 3 11 2 69
N06 PSYCHOANALEPTICS 62 2 10 20 7 1 102
N06A Antidepressants 37 1 7 12 7 1 65
N06B Psychostimulants, agents used for ADHD and nootropics 22 3 4 29
N06C Psycholeptics and psychonaleptics in combination 2 2
N06D Anti-dementia drugs 1 1 4 6
N07 OTHER NERVIOUS SYSTEM DRUGS 14 2 3 9 1 3 32
N07A Parasympathomimetics 6 2 1 9
N07B Drugs used in addictive disorders 2 2 1 4 1 2 12
N07C Antivertigo preparations 2 1 2 5
N07X Other nervous system drugs 4 1 1 6
Total 346 9 30 86 53 36 560
S. Ravera et al.
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to the single medicine, given to an adult, for its main indi-
cation, in a normal dosage,and at the start of the treatment
[7, 8, 17]. Therefore, if a medication is not prescribed
according to these conditions, it is crucial to bear in mind
that the categorization system can only be used as back-
ground information, and it is necessary to carefully assess
all the individual risk factors and avoid strict adherence to
the medication classification. Furthermore, the system is
focused on the effects of medications on fitness to drive
and, consequently, the role of the disease, which could also
influence fitness to drive, is not considered and certainly
needs further attention while counselling the patient [7, 8].
Finally, the categorization system should always be
associated with proper patient counselling in order to
avoid any misunderstandings from the patient’s side and
to ensure that the patient receives adequate information
allowing him/her to make a consistent decision with the
message given by the medication category.
Next steps and recommendations
The categorization system presented in this manuscript
was developed within the DRUID project and, therefore, in
a European context. As a consequence, the DRUID partners
agreed that the European regulatory authorities should to
be informed about this categorization process.This should
lead to discussion and consensus on the criteria hereby
proposed and special efforts should be carried out
to implement the current system at both international
and national level, with consideration country specific
circumstances.
In this respect, it is important to underline that the
DRUID consortium [31] previously approached the EMA
Pharmacovigilance Working Party (PhVWP) in order to
obtain its contribution in relation to the development of
the categorization/labelling system for medications that
impair driving [32]. In June 2011, the PhVWP agreed that
any information on the influence of medicines on driving
ability should be simple and helpful to the patient and,
therefore, be reflected in the package leaflet. Furthermore,
the PhVWP recommended including in the package leaflet
a two-tier risk classification system differentiating between
medicinal products with a potential for relevant influence
on driving (moderate or major influence) and medicinal
products without a potential for relevant influence (no or
minor influence). Finally, the PhVWP recognized that this
two-tier risk classification system could be further divided
to include a maximum of four categories at the discretion
of Member States [32].This consensus is an important step
in the harmonization of information on the potential for a
medicine’s impairing effects on fitness to drive. However, it
would be desirable for Member States to be provided with
further discretionary activities, which could be used to
reinforce the awareness of HCPs and patients on the
effects of medicines on fitness to drive.
Since the categorization requires constant revision, it is
also advised that an expert working group on medicines
and driving be established to keep the system functional,
up-to-date, and reliable.
Furthermore, it is recommended that special attention
be paid to educating those who might play an active role
in traffic safety. In this respect, medical and pharmacy
schools should develop targeted educational programmes
covering the issue of medication use and driving. Police
officers and driving instructors should be adequately
trained on this topic so that they are able to transfer knowl-
edge about the effects of certain medications on a per-
son’s ability to drive to potential patients who may drive in
traffic.
Finally, a guideline should be developed to explain the
use of the categorization system to HCPs and to serve as a
support mechanism in the decision making process. On
the other hand, since the PIL is the most accessible source
of information for patients, it would also be advisable to
develop an effective strategy to communicate the risk
related to the use of medicines and driving. For instance, a
straightforward grading system could be included in the
patient package leaflet and warning labels in the form of
pictograms could be printed on the medication box to
provide clear instructions about the use of the medication
and driving to patients.
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